MOUNTAINEER and DESTINY-CRC01 Trials Expand Second-Line Options for HER2+ mCRC
April 15th 2023Alaa Muslimani, MD, discusses the significance of the phase 2 DESTINY-CRC01 and MOUNTAINEER-03 trials on HER2-positive metastatic colorectal cancer treatment in the second line, efforts to expand the use of these agents in earlier disease settings, and the need for more robust clinical data and larger investigations for this population.
Research Clarifies Treatment Patterns and Raises New Questions Across GI Cancers
March 23rd 2023Jimmy Hwang, MD, discusses findings supporting the use of immunotherapy in hepatocellular carcinoma and biliary tract cancer, the potential benefits of antibody-drug conjugates in metastatic colorectal cancer, and unmet needs in esophageal squamous cell carcinoma and rectal cancer.
Dr. Brown on the Use of PARP Inhibitors in the Upfront and Recurrent Settings in Ovarian Cancer
March 17th 2023Jubilee Brown, MD, professor, director, gynecologic oncology, Levine Cancer Institute, Atrium Health, discusses benefits associated with PARP inhibitor maintenance therapy in the upfront and recurrent settings of ovarian cancer.
PARP Inhibitors Redefine the Rapidly Changing Ovarian Cancer Landscape
March 15th 2023Erin K. Crane, MD, MPH, describes practice-changing findings from upfront trials with niraparib and olaparib, contextualizes the significance of the manufacturer restrictions of later-line PARP inhibitors for ovarian cancer, and predicts further research efforts in this population.
Developing Culturally Concordant Palliative Care for Hindu Patients and Families
January 18th 2023Sometimes, clinicians do not acknowledge how patients' values and beliefs influence how they ascribe meaning to their illness, how they prefer to receive information, and how they make decisions until the end-of-life stage, leading to misunderstandings between clinicians and patients.
Luveltamab Tazevibulin Shows Encouraging Activity in Frα-Selected Advanced Ovarian Cancer
January 11th 2023Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.
Crane Helps Fellows Navigate a Fraught Time in Gynecology
Erin K. Crane, MD, MPH, talked to Oncology Fellows about helping trainees care for their own health and wellness, navigate the politics surrounding gynecologic care, and the lessons she hopes they take away from the program.
Crane Helps Gynecologic Fellows Deliver Care in a Complicated Time
November 21st 2022Dr Crane discusses why Atrium Health decided to launch a gyn onc fellowship, how she helps fellows navigate the current political landscape while maintaining high-level care, and how she tries to model a good work-life balance for her trainees.
CAR T-Cell Therapies Improve Treatment Landscape in Relapsed/Refractory Multiple Myeloma
November 8th 2022The increasing integration of CAR T-cell therapies into the treatment paradigm for adult patients with relapsed or refractory multiple myeloma addresses several unmet needs and improves outcomes for this historically limited patient population.
Atrium Health Levine Cancer Institute’s Breast Program Earns NAPBC Accreditation
November 7th 2022Atrium Health Levine Cancer Institute’s breast cancer program has been granted accredited status by the National Accreditation Program for Breast Centers, a quality program administered by the American College of Surgeons.